信达生物(01801.HK)发布公告,其合作伙伴Ollin Biosciences, Inc.(Ollin)已与强生(Johnson & Johnson, NYSE: JNJ)达成收购协议。Ollin核心管线OLN324(信达生物研发代号:IBI324)由信达生物研发并对外授权。
本文源自:金融界AI电报
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.